AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
US-based diagnostic software company Arkstone Medical Solutions has partnered with Peruvian medical technology company Neslab ...
Antibiotics are often thought of as an easy cure to bacterial infections, but they could be fueling an urgent public health ...
Researchers have used artificial intelligence to identify 25 new protein compounds that can kill bacteria and fungi, ...
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
A groundbreaking cannabinoid-based antimicrobial, Silvanex, fights drug-resistant infections with a synergy of silver, CBC ...
The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback